Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
NCT04903314Phase 1Completed
- Sponsor
- SK Life Science, Inc.
- Start
- May 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of cenobamate in partial epilepsy (4 cohorts), sponsored by SK Life Science, Inc. Primary endpoints: Area Under the Curve at 18 months and Maximum Plasma Concentration at 18 months. Started May 2021; status: completed.
02
Drugs
cenobamate
03
Conditions
partial epilepsy
Beyond the preview
Go deeper on NCT04903314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903314.